![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/46ec52c912ed88cc055bb46b5d6cdda20daa7aa3-5472x3648.jpg?fit=crop&auto=format)
Oral Treatment Shows Promise in Combating Alzheimer Disease
ALZ-801 has now progressed to the phase 3 APOLLOE4 study, designed to evaluate efficacy, safety, and biomarker and imaging effects.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/d391f6349719426f2859b5a47b8620a68d3f635f-7164x4781.jpg?fit=crop&auto=format)
Obesity, Emaciated BMI Associated With Poor Prognosis in Pediatric B-Cell Non-Hodgkin Lymphoma
Surprisingly, those with overweight BMI at diagnosis did not have a poor prognosis.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
All News | Page 1298
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/f2f96ceab0190f01a153af7be7d52233b22d1cad-6000x4000.jpg?fit=crop&auto=format)
New Perspectives in CML Management: Personalized Approaches and Adaptive Strategies
Optimizing outcomes for patients with chronic myeloid leukemia (CML) requires personalized treatment, adaptive dosing, and precise genetic insights.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/b36dd81aa90a138e5133339bf5d87c25700b3d9a-4000x3000.jpg?fit=crop&auto=format)
FDA Grants Orphan Drug Designation for ABD-147 for Neuroendocrine Carcinoma
Previously, the FDA granted fast track designation to ABD-147 (Abdera Therapeutics Inc) for extensive stage small cell lung cancer.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
Madison Gill, PharmD Candidate
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
Allyson Gill, PharmD Candidate
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
Ajay Sharma, PhD, RPh, MPharm, PGDCR
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8a2364a9c72988668de6f891e44771df2dbfaf39-6415x4277.jpg?fit=crop&auto=format)
Advancing Immunotherapy and Combination Treatments for T-Cell Lymphoma
Stefan Barta, MD, MS, MRCPCUK, discusses the potential role of biomarkers in predicting treatment outcomes, the emerging use of CAR T-cell therapy, and the benefits and challenges of combination therapies in managing T-cell lymphoma.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
Khemraj Hirani, PhD, RPh, MBA, MPharm, RAC, CIP, CCRP
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/055f003a0f9441c456494e803cd3faf34a7eab31-7489x4197.jpg?fit=crop&auto=format)
Exploring T-Cell–Directed Therapies for Indolent B-Cell Lymphoma
Sonali Smith, MD, discusses T-cell–directed therapies for indolent B-cell lymphoma, focusing on their efficacy, FDA-approved treatments, and treatment challenges, such as managing cytokine release syndrome.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/b6a997bc48efbd9e0055ee2bbf7ce4ce657e1fad-7360x4912.jpg?fit=crop&auto=format)
Are OTC Proton Pump Inhibitors a Boon Or a Curse?
The risk of therapy duplication with OTC and prescription PPIs can be lowered with an innovative, multi-faceted, and intentional approach by pharmacy teams and prescribers.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/69a6102da7f640ffb7bd61aab8d785eee95d8637-5964x3355.jpg?fit=crop&auto=format)
Pharmacists Can Counsel Pregnant Individuals Seeking Iron Supplementation
There is no significant impact on maternal or infant health outcomes when taking an additional iron supplement
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/3e123221a6782438d720b701d1c3273334c2b6bd-9504x6336.jpg?fit=crop&auto=format)
IVIG Shows Promise as Therapy in Patients With Recurrent Implantation Failure
Intravenous immunoglobulin (IVIG) therapy was found to have statistically significant positive effects on live birth rates, implantation rate, and other indicators.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
Pearl Steinzor
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/d50e215fc630916cc4620c92fc21635e20e7dd80-5824x3264.jpg?fit=crop&auto=format)
Key Strategies Released for Integrating Equity Into Health Technology Assessment
The Center for Innovation & Value Research has released a final report recommending strategies to ensure health equity is integrated into health technology assessment, which can influence drug pricing
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/93c9023d60a22e04f2b861927dc7afb5f37edc3b-4800x3200.jpg?fit=crop&auto=format)
Staying Up to Date With Routine Vaccinations is Crucial to Slowing Spread, Expert Says
Lauren Posteraro, PharmD, a pharmacist with AHN, discusses how misinformation and access to technology can contribute to vaccine hesitancy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/d80291b1bdd0e6917f4bbb250c8d2a64a13e71d0-7665x4987.jpg?fit=crop&auto=format)
How Pharmacy Educators Are Using Social Media to Engage and Inspire Students
Educators describe a project where they used TikTok to encourage students to develop innovative informatics and medication safety technologies for fun, engaging learning.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/256bf32ede397094de588a94ae1bc70f93d69123-6144x3072.jpg?fit=crop&auto=format)
Bridging Health Equity: Addressing Heart Failure in Native American Communities
New insights into heart failure risks in Native American communities are highlighting the need to address social determinants of health.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/1e46271e9ce9710b400fb8fc485af9b644792543-7360x4912.jpg?fit=crop&auto=format)
FDA Grants Regenerative Medicine Advanced Therapy Designation for OBX-115
OBX-115 could offer further treatment options for individuals with advanced or metastatic melanoma by enhancing persistence, antitumor activity, and clinical safety of TIL cell therapy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/f063ed19e48b31d51cd15b9892c5fe74cb2898b7-5639x3759.jpg?fit=crop&auto=format)
Women Who Receive False Positive Mammography Results Are Less Likely to Attend Follow-Up Screenings
The authors stress that health care providers should explain false positive results to their patients, reassure them that results may be negative, and stress the significance of continued screenings.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/c8e9c7baf040ca10b6cabeb41f3e9ab84d4be1df-5376x3584.jpg?fit=crop&auto=format)
Clinical Updates in Alirocumab Injection
Alirocumab (Praluent; Regeneron), is a PCSK9 inhibitor indicated for the treatment of adults with heterozygous familiar hypercholesterolemia (HeFH) or atherosclerotic cardiovascular disease.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/f3b76e8741cd1e81eeb1990adf49d0389fd9e602-4928x3264.jpg?fit=crop&auto=format)
FDA Approves Diagnostics for Olaparib, Abiraterone Combination Therapy in Patients With BRCA-Mutated mCRPC
These companion diagnostics are poised to provide simpler and detailed insights into a patient’s genomic alternations, which could improve outcomes for patients with prostate cancer.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/8caeef59f80cc65922c8d847c59531a6b81d5ca2-2551x901.png)
Myelofibrosis
Pharmacy Times offers the latest news and insights for the pharmacy professional and solutions that impact the everyday practice of pharmacy.
![](https://cdn.sanity.io/images/0vv8moc6/pharmacytimes/fa03ba8af5e97973f341183f007658db26ad3186-5380x2925.jpg?fit=crop&auto=format)
Tolebrutinib Shows Reduction in Disability Accumulation in Non-Relapsing Secondary Progressive Multiple Sclerosis
In a promising development in multiple sclerosis research, tolebrutinib delayed the onset of disability progression in patients with nrSPMS.